HMGB1 treatment resulted in significant upregulation of stem cell markers (Oct4 and Nanog) and CD133+ cell proportion in fresh tumor tissues, which were abrogated by silencing TLR2, YAP, or HIF-1α (Fig. 6b, c). Here, POU5F1 is linked to neoplasm.